A Novel high-efficiency quantitative control of mitochondrial transfer based on droplet microfluidics and its application on muscle regeneration
Invited conference paper presented and published in conference proceedings
CUHK Authors
Full Text
There are no full text file(s) associated with this record. |
Other information
AbstractIntroduction
Mitochondrial transfer is reported to restore the function of damaged cells. The transfer of mitochondria to cell therapy products prior to their administration can enhance therapeutic outcomes. However, the low efficiency of previously reported methods limits its clinical application. Here, we developed a novel droplet microfluidics-based mitochondrial transfer technique that can achieve high-efficiency and high-throughput quantitative mitochondrial transfer to single cells.
Methods
C2C12 was used to test the cell viability and myogenic differentiation ability and ATP production. 3-month-old C57 male mice were randomly divided into control and treatment groups with various quantity of transferred mitochondria. A muscle injury model was as proof-of-concept model. Treatment started at day 3, and tissue collection at Day 7 for qPCR, histological, muscle functional tests . One-way or two-way ANOVA with post-hoc tests were used for multiple-group comparisons.
Results
The cell viability, differentiation ability, and ATP production were positively correlated with the number of mitochondria transferred into cells. Muscle functions and whole-body grip strengthwere significantly improved upon administration of cells with prior low number of mitochondrial transfer.
Conclusion
In summary, we reported a highly efficient and quantitative controllable mitochondrial transfer platform which can enhance the cellular activity before administration. This technique can considerably promote the clinical application of mitochondrial transfer with optimized cell function improvements for cell therapy.
Mitochondrial transfer is reported to restore the function of damaged cells. The transfer of mitochondria to cell therapy products prior to their administration can enhance therapeutic outcomes. However, the low efficiency of previously reported methods limits its clinical application. Here, we developed a novel droplet microfluidics-based mitochondrial transfer technique that can achieve high-efficiency and high-throughput quantitative mitochondrial transfer to single cells.
Methods
C2C12 was used to test the cell viability and myogenic differentiation ability and ATP production. 3-month-old C57 male mice were randomly divided into control and treatment groups with various quantity of transferred mitochondria. A muscle injury model was as proof-of-concept model. Treatment started at day 3, and tissue collection at Day 7 for qPCR, histological, muscle functional tests . One-way or two-way ANOVA with post-hoc tests were used for multiple-group comparisons.
Results
The cell viability, differentiation ability, and ATP production were positively correlated with the number of mitochondria transferred into cells. Muscle functions and whole-body grip strengthwere significantly improved upon administration of cells with prior low number of mitochondrial transfer.
Conclusion
In summary, we reported a highly efficient and quantitative controllable mitochondrial transfer platform which can enhance the cellular activity before administration. This technique can considerably promote the clinical application of mitochondrial transfer with optimized cell function improvements for cell therapy.
All Author(s) ListLo Hiu Tung Jessica, Sun Jiayu, Fan Lei, Yiu Tsz Lam, Shakoor Adnan, Li Gang, Wayne Yuk Wai Lee, Sun Dong
Name of ConferenceThe Hong Kong Orthopaedic Association 2022 Annual Congress
Start Date of Conference05/11/2022
End Date of Conference06/11/2022
Place of ConferenceHong Kong
Country/Region of ConferenceHong Kong
Year2022
LanguagesEnglish-United States
